Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

Lancet

Volumn 362, Issue 9381, 2003, Pages 362-369

  Chang, Jenny C ^a,b   Wooten, Eric C ^a   Tsimelzon, Anna ^a   Hilsenbeck, Susan G ^a   Gutierrez, M Carolina ^a   Elledge, Richard ^a   Mohsin, Syed ^a   Osborne, C Kent ^a   Chamness, Gary C ^a   Allred, D Craig ^a   O'Connell, Peter ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DOCETAXEL; GENE PRODUCT; RNA;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; CANCER PATIENT; CELL ADHESION; CELL CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSKELETON; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TREATMENT OUTCOME;

EID: 0042125511     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14023-8     Document Type: Article

References (34)

1. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet. 339:1992;1-15. review.
2. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet. 339:1992;71-85.
3. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 351:1998;1451-1467.
4. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 352:1998;930-942.
5. Hortobagyi G.N. Docetaxel in breast cancer and a rationale for combination therapy. Oncology. 11:1997;11-15.
6. Chan S., Friedrichs K., Noel D., et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer: the 303 Study Group. J Clin Oncol. 17:1999;2341-2354.
7. Nabholtz J.M., Patterson A., Dirix L., et al. A phase III trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) (TAC) to (FAC) as first line chemotherapy for patients with metastatic breast cancer. Proc Am Soc Clin Oncol. 20:2001;22a.
8. Henderson I.C., Berry D.A., Demetri G.D., et al. Improved disease free survival and overall survival from the addition of sequential paclitaxel but not from escalation of doxorubicin in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc Am Soc Clin Oncol. 17:1998;101.
9. Aapro M.S. Adjuvant therapy of primary breast cancer: a review of key finding s from the 8th international conference, St Gallen. Oncologist. 6:2001;376-385.
10. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 16:1998;2672-2685.
11. Mamounas E.P. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel. Oncology. 11:(suppl 6):1997;37-40.
12. Schena M., Shalon D., Davis R.W., Brown P.O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 270:1995;467-470.
13. Khan J., Simon R., Bittner M., et al. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Research. 58:1998;5009-5013.
14. Lockhart D.J., Dong H., Byrne M.C., et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nature Biotechnology. 14:1996;1675-1680.
15. Sgroi D.C., Teng S., Robinson G., LeVangie R., Hudson J.R., Elkahloun A.G. In vivo gene expression profile analysis of human breast cancer progression. Cancer Res. 59:1999;5656-5661.
16. Perou C.M., Jeffrey S.S., van de Run M., et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA. 96:1999;9212-9217.
17. Whitehead Institute/MIT centre for genome research. Primer 3. http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi (accessed May 17, 2003).
18. van't Veer L.J., Dai H., van De Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536.
19. Schadt E.E., Li C., Ellis B., Wong W.H. Feature extraction and normalization algorithms for high-density oligonucleotide gene expression array data. J Cell Biochem Suppl. 37:(suppl 37):2001;120-125.
20. Li C., Wong W.H. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA. 98:2001;31-36.
21. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol 2001; 2: research0032.1-0032.11.
22. Simon R, Peng A. http://linus.nci.nih.gov/BRB-ArrayTools.html (accessed May 17, 2003).
23. Radmacher M.D., McShane L.M., Simon R. A paradigm for class prediction using gene expression profiles. J Comput Biol. 9:2002;505-511.
24. Ambroise C., McLachlan G.J. Selection bias in gene extraction on the basis of microarray gene-expression data. Proc Natl Acad Sci USA. 99:2002;6562-6566.
25. Simon R., Radmacher M.D., Dobbin K., McShane L.M. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst. 95:2003;14-18.
26. NCBI. Gene expression omnibus: accession numbers GSE 349 (resistant samples) and GSE 350 (sensitive samples). http://www.ncbi.nlm.nih.gov/geo (accessed May 17, 2003).
27. Van Poznak C., Tan L., Panageas K.S., et al. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J Clin Oncol. 20:2002;2319-2326.
28. Dumontet C., Sikic B.I. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol. 17:1999;1061-1070.
29. Anand S., Penrhyn-Lowe S., Venkitaraman A.R. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell. 3:2003;51-62.
30. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 347:2002;1999-2009.
31. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:2001;10869-10874.
32. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature. 406:2000;747-752.
33. Hansen R.K., Parra I., Lemieux P., Oesterreich S., Hilsenbeck S.G., Fuqua S.A. Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat. 56:1999;187-196.
34. Osborne C.K., Yochmowitz M.G., Knight W.A. III, McGuire W.L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 46:(suppl 12):1980;2884-2888.